These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 35083192)

  • 1. Evaluating the Impact of SARS-CoV-2 Variants on the COVID-19 Epidemic and Social Restoration in the United States: A Mathematical Modelling Study.
    Li R; Li Y; Zou Z; Liu Y; Li X; Zhuang G; Shen M; Zhang L
    Front Public Health; 2021; 9():801763. PubMed ID: 35083192
    [No Abstract]   [Full Text] [Related]  

  • 2. Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use.
    Shen M; Zu J; Fairley CK; Pagán JA; An L; Du Z; Guo Y; Rong L; Xiao Y; Zhuang G; Li Y; Zhang L
    Vaccine; 2021 Apr; 39(16):2295-2302. PubMed ID: 33771391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Sonabend R; Whittles LK; Imai N; Perez-Guzman PN; Knock ES; Rawson T; Gaythorpe KAM; Djaafara BA; Hinsley W; FitzJohn RG; Lees JA; Kanapram DT; Volz EM; Ghani AC; Ferguson NM; Baguelin M; Cori A
    Lancet; 2021 Nov; 398(10313):1825-1835. PubMed ID: 34717829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitigating the SARS-CoV-2 Delta disease burden in Australia by non-pharmaceutical interventions and vaccinating children: a modelling analysis.
    Milne GJ; Carrivick J; Whyatt D
    BMC Med; 2022 Feb; 20(1):80. PubMed ID: 35177062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans.
    Young-Xu Y; Korves C; Roberts J; Powell EI; Zwain GM; Smith J; Izurieta HS
    JAMA Netw Open; 2021 Oct; 4(10):e2128391. PubMed ID: 34613401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts.
    Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S
    Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
    Zou Y; Huang D; Jiang Q; Guo Y; Chen C
    Front Public Health; 2022; 10():940956. PubMed ID: 35910897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccine is correlated with favourable epidemiological indicators in the Auvergne-Rhône-Alpes region (France): An ecological study.
    Romain-Scelle N; Elias C; Vanhems P
    Vaccine; 2022 Jan; 40(5):695-700. PubMed ID: 34969543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis.
    Xu S; Li J; Wang H; Wang F; Yin Z; Wang Z
    BMC Med; 2023 Apr; 21(1):160. PubMed ID: 37106390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Considerations on vaccines and immunization against COVID-19 for epidemic control in China].
    Zhang Q; Wang FZ; Ma C; An ZJ; Yin ZD
    Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1371-1376. PubMed ID: 34963231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voluntary risk mitigation behaviour can reduce impact of SARS-CoV-2: a real-time modelling study of the January 2022 Omicron wave in England.
    Brooks-Pollock E; Northstone K; Pellis L; Scarabel F; Thomas A; Nixon E; Matthews DA; Bowyer V; Garcia MP; Steves CJ; Timpson NJ; Danon L
    BMC Med; 2023 Jan; 21(1):25. PubMed ID: 36658548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil.
    Ferreira LS; de Almeida GB; Borges ME; Simon LM; Poloni S; Bagattini ÂM; da Rosa MQM; Diniz Filho JAF; Kuchenbecker RS; Camey SA; Kraenkel RA; Coutinho RM; Toscano CM
    Vaccine; 2022 Nov; 40(46):6616-6624. PubMed ID: 36210250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study.
    Bruxvoort KJ; Sy LS; Qian L; Ackerson BK; Luo Y; Lee GS; Tian Y; Florea A; Aragones M; Tubert JE; Takhar HS; Ku JH; Paila YD; Talarico CA; Tseng HF
    BMJ; 2021 Dec; 375():e068848. PubMed ID: 34911691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United States.
    Yang F; Tran TN; Howerton E; Boni MF; Servadio JL
    BMC Med; 2023 Aug; 21(1):321. PubMed ID: 37620926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.